Health Editor’s Note: Currently the antiviral remdesivir is being given by intravenous infusions to COVID-19 patients and has been shown to shorten the time to recovery. Gilead has been given the go ahead to work on an inhaled version which will be far easier to give to a patient. An inhaled version would allow for dosing outside a hospital atmosphere and also for earlier treatment…..Carol
Gilead is about to start trials of an inhaled version of remdesivir
After receiving the green light from the FDA to move forward, Gilead is about to start trials of an inhaled version of remdesivir. We will screen healthy volunteers for Phase 1 trials this week and hope to begin studies in patients with COVID-19 in August. If the trials are successful, this could represent important progress. Remdesivir, our investigational antiviral medicine, is currently given to patients intravenously through daily infusions in the hospital. An inhaled formulation would be given through a nebulizer, which could potentially allow for easier administration outside the hospital, at earlier stages of disease. That could have significant implications in helping to stem the tide of the pandemic.
We have already learned a lot about how remdesivir works in a relatively short space of time. All of us at Gilead are grateful for the strong collaborations that helped to make this possible and to the thousands of patients who have taken part in clinical trials. Remdesivir is now being used to treat patients through emergency use authorizations and other access programs around the world. And yet, we still have some way to go in exploring the full potential of remdesivir to help against COVID-19.